Immunome Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
During the quarter ended December 31, 2025, three of our executive officers adopted Rule 10b5-1 trading plans, which are set forth in the table below.
| Name and Position · Action · Adoption/TerminationDate · Rule 10b5-1(1) · Non-Rule10b5-1(2) · Total Shares ofCommon Stockto be Sold · ExpirationDate | |||||
|---|---|---|---|---|---|
| Robert Lechleider, Chief Medical Officer | Adoption | December 24, 2025 | X | 110,000 | December 31, 2026 |
| Jack Higgins, Chief Scientific Officer | Adoption | December 19, 2025 | X | 37,729 | December 31, 2026 |
| Max Rosett, Chief Financial Officer | Adoption | December 26, 2025 | X | 125,000 | September 30, 2026 |
(1)
Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2)
"Non-Rule 10b5-1 trading arrangement" as defined in Item 408(c) of Regulation S-K under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.